In addition to the HER2-amplified breast cancer cell line BT474, HER2-MCF7 cells also showed EGFR downregulation by DCA/tamoxifen, suggesting that the combination treatment will be applicable to HER2-postive breast cancer. Here, ERBB2 is linked to breast carcinoma.